Only in French: Lettre ouverte – Rédigée par Mme Marie-Pierre Ippersiel, présidente et directrice générale, PRIMA Québec, et co-signée par les Directeurs généraux des RSRI * Dans sa mise à jour économique du 30 novembre, le gouvernement du Canada annonçait 250M$ sur cinq ans, à partir de l’an prochain, pour appuyer les entreprises en innovation afin de stimuler leur croissance … Read More
CQDM is proud to contribute to the success of Medicago and its partners, winners of the 2020 RSRI Innovation Award from ADRIQ
Montréal (Quebec), November 19, 2020 — The prize rewards VLPExpressTM, a plant-based vaccine discovery platform developed by Medicago in collaboration with McGill and Laval universities. The project was funded in 2009 by CQDM with contributions from Pfizer, Merck, the Ministère de l’Économie et de l’Innovation, and the Business-Led Networks of Centres of Excellence program from the federal government (BL-NCE). Typically, … Read More
CQDM portfolio company Mesentech secures new capital to bring lead product to clinical phase
Montreal – November 11 2020 – CQDM congratulates Mesentech on securing additional investment to support the clinical development of their bone-targeting drug candidate MES-1007, a drug with the potential to reverse bone wastage in Duchenne Muscular Dystrophy and other skeletal fragility diseases in pediatrics. Link to Mesentech’s Press Release: click here. “CQDM’s investment enabled Mesentech to generate the safety data … Read More
CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials
A collaboration between Perceiv AI, DalCor Pharmaceuticals and the Montreal Heart Institute Montreal (Quebec), November 5, 2020 — The CQDM is pleased to announce the launch of a $600,000 collaborative project in biopharma and artificial intelligence (AI) to develop an AI-driven precision medicine tool. Under the leadership of Dr. Christian Dansereau, CEO of Perceiv AI, in collaboration with Dr. Jean-Claude Tardif, director … Read More
Philip Tagari Appointed to CQDM’s Board of Directors
Montreal, October 5th, 2020 – Richard Fajzel, Chairman of CQDM’s Board of Directors and Diane Gosselin, President and CEO of CQDM are pleased to announce the appointment of Philip Tagari to the Board of Directors. Philip Tagari is currently Vice President of Research (Therapeutic Discovery) at Amgen Inc., one of the world’s leading biotechnology companies. His impressive track record spans … Read More
CQDM Awards a Grant to Centre de Recherche du CHU de Québec-Université Laval …
CQDM Awards a Grant to Centre de Recherche du CHU de Québec-Université Laval for a Study Collaboration With Merck Canada to Identify Biomarkers of Response to Pembrolizumab in Patients with Localized but Aggressive Prostate Cancer Montreal, July 20, 2020 – CQDM is pleased to announce a grant for a collaboration among Centre de recherche du CHU de Québec-Université Laval, Merck … Read More
nplex-McGill partnership selected by CQDM for a $1M grant to apply next-generation ELISA in drug discovery
July 16, 2020 (Montreal, Quebec) – McGill University and CQDM announced today that a collaborative project between McGill and nplex biosciences to further develop a highly-scalable protein detection method, termed the “nELISA”, has been selected for funding by CQDM. The research team will receive a $1,000,000 grant for one year through the CQDM Quantum Leap program. Contributing to the CQDM … Read More
CQDM announces funding to develop a test to predict disease progression in patients infected with COVID-19
Montréal (Québec), July 14, 2020 – The biopharmaceutical research consortium CQDM is pleased to announce the launch of a project valued at over $300,000 to support the development of a molecular test designed to assess, among others, the risk of death in COVID-19 patients. The initiative proposed by MRM Proteomics Inc. is made possible with $158,000 in funding from the … Read More
CQDM becomes a shareholder of Mesentech to support the validation of a highly promising bone-targeting drug delivery technology
Montreal, June 22, 2020. CQDM is pleased to announce an investment in Mesentech Inc., an emerging biotech based in Vancouver, British Columbia, developing a bone-targeting technology platform to deliver drugs selectively to bone-tissue. The lead program, MES-1007, aims to restore bone density and strength in conditions such as osteogenesis imperfecta (brittle bone disease), congenital muscular dystrophies (including Duchenne), renal osteodystrophy … Read More
Health Innovation: Investing Now to Face the Crises of Tomorrow
Open letter – Published in the Hill Times (Ottawa) June 29th 2020 (https://www.hilltimes.com/2020/06/29/health-innovation-investing-now-to-face-the-crises-of-tomorrow/254763) & Published on LaPresse website June 20th 2020 (https://www.lapresse.ca/debats/opinions/2020-06-20/innovation-en-sante-investissons-maintenant-pour-faire-face-aux-crises-de-demain) Health innovation will play a key part in the battle against the devastating effects of the COVID-19 pandemic. As we have been doing since the beginning of the crisis, the leaders of the innovation ecosystem that includes our … Read More
